Actinium Makes New Appointments
This article was originally published in Scrip
Actinium Pharmaceuticals, Inc. has appointed Kevin Zikaras senior clinical scientist and Rowena Choudrie senior director, pharmaceutical product development. Zikaras joins Actinium from Bristol-Myers Squibb where he was clinical protocol manager in the immuno-oncology group and prior to this he was clinical research manager at Columbia University Medical Center. Choudrie has over 20 years' experience in the pharma industry and most recently was senior director, pharma development, global technical operations at NPS Pharmaceuticals. Previously, she worked at Palatin Technologies, Inc. as director, formulation development and manufacturing.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.